Sheppard Dean
Division of Pulmonary, Critical Care, Allergy, and Sleep, and Lung Biology Center, University of California, San Francisco, San Francisco, California.
Ann Am Thorac Soc. 2015 Mar;12 Suppl 1(Suppl 1):S21-3. doi: 10.1513/AnnalsATS.201406-245MG.
Transforming growth factor-β (TGF-β) plays a central role in driving tissue fibrosis. TGF-β is secreted in a latent form, held latent by noncovalent association of the active cytokine with a peptide derived from cleavage of the N-terminal domain of the same gene product, and needs to be activated extracellularly to exert any of its diverse biological effects. We have shown that two of the three mammalian isoforms of TGF-β, TGF-β1 and TGF-β3, depend on interactions with cell surface integrins for activation. We found that the integrin αvβ6 is highly induced on injured alveolar epithelial cells, potently induces TGF-β activation, and is critical for the development of pulmonary fibrosis and acute lung injury. However, although TGF-β drives fibrosis in virtually every anatomic site, αvβ6-mediated TGF-β activation is much more restricted. For example, αvβ6 is not induced on injured hepatocytes and plays little or no role in cirrhosis induced by repetitive hepatocyte injury. Fibroblasts are highly contractile cells that express multiple integrins closely related to αvβ6, which share the promiscuous αv subunit, so we reasoned that perhaps one or more of these αv integrins on fibroblasts might substitute for αvβ6 and activate the TGF-β required to drive liver fibrosis. Indeed, deletion of the αv subunit from activated fibroblasts protected mice from carbon tetrachloride-induced liver fibrosis. Importantly, these same mice were protected from bleomycin-induced pulmonary fibrosis and renal fibrosis caused by unilateral ureteral obstruction, despite the presence of epithelial αvβ6 in these mice. These results suggest that the generation and maintenance of sufficient quantities of active TGF-β to cause tissue fibrosis in multiple organs probably depends on at least two sources-TGF-β activation by injured epithelial cells that drives fibroblast expansion and activation and an amplification step that involves TGF-β activation by an αv integrin on activated fibroblasts. These results suggest that intervening at either of these steps could be useful for the treatment of fibrotic diseases.
转化生长因子-β(TGF-β)在驱动组织纤维化过程中发挥着核心作用。TGF-β以潜伏形式分泌,活性细胞因子通过与源自同一基因产物N端结构域裂解产生的肽非共价结合而保持潜伏状态,并且需要在细胞外被激活才能发挥其多种生物学效应。我们已经表明,TGF-β的三种哺乳动物异构体中的两种,即TGF-β1和TGF-β3,其激活依赖于与细胞表面整合素的相互作用。我们发现整合素αvβ6在受损的肺泡上皮细胞上高度诱导表达,能有效诱导TGF-β激活,并且对肺纤维化和急性肺损伤的发展至关重要。然而,尽管TGF-β几乎在每个解剖部位都能驱动纤维化,但αvβ6介导的TGF-β激活却受到更多限制。例如,αvβ6在受损的肝细胞上不会被诱导表达,并且在重复性肝细胞损伤诱导的肝硬化中作用很小或没有作用。成纤维细胞是高度可收缩的细胞,表达多种与αvβ6密切相关的整合素,它们共享混杂的αv亚基,因此我们推测成纤维细胞上的这些αv整合素中的一种或多种可能替代αvβ6并激活驱动肝纤维化所需的TGF-β。事实上,从活化的成纤维细胞中删除αv亚基可保护小鼠免受四氯化碳诱导的肝纤维化。重要的是,尽管这些小鼠存在上皮αvβ6,但相同的小鼠也受到保护,免受博来霉素诱导的肺纤维化和单侧输尿管梗阻引起的肾纤维化。这些结果表明,在多个器官中产生和维持足以导致组织纤维化的活性TGF-β的量可能至少取决于两个来源——受损上皮细胞激活TGF-β以驱动成纤维细胞增殖和激活,以及一个放大步骤,即活化的成纤维细胞上的αv整合素激活TGF-β。这些结果表明,在这两个步骤中的任何一个进行干预都可能对纤维化疾病的治疗有用。